We are live on ! Find out more
VBIV

VBI Vaccines, Inc. New Common Stock (Canada)
VBIV

Delisted

VBIV was delisted on the 7th of August, 2024.

Back to rankings

41 hedge funds and large institutions have $1.79M invested in VBI Vaccines, Inc. New Common Stock (Canada) in 2024 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 5 increasing their positions, 11 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

167% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 3

14% more funds holding

Funds holding: 36 → 41 (+5)

11% more capital invested

Capital invested by funds: $1.61M → $1.79M (+$176K)

55% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 11

Holders
41
Holders Change
+5
Holders Change %
+13.89%
% of All Funds
0.59%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
5
Reduced
11
Closed
3
Calls
$543K
Puts
–
Net Calls
+$543K
Net Calls Change
+$59K

Top Buyers

Rank Fund Capital Flow
1
Geode Capital Management
Geode Capital Management
Massachusetts
+$21.9K
2
XT
XTX Topco
Cayman Islands
+$17.5K
3
AGC
Aspen Grove Capital
Colorado
+$12.4K
4
Simplex Trading
Simplex Trading
Illinois
+$12K
5
Citadel Advisors
Citadel Advisors
Florida
+$10.4K

Top Sellers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
-$18.8K
2
Renaissance Technologies
Renaissance Technologies
New York
-$17.8K
3
AGM
Alpine Global Management
New York
-$15.1K
4
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$11.1K
5
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors
Iowa
-$10.6K

VBIV Hedge Fund Activity: Q2 2024 in Review

41 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) for Q2 2024, worth a combined $1.79M — up 11% from $1.61M a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new VBIV positions and 3 closed out — a net gain of 5 holders — while 5 added to existing stakes and 11 trimmed.

The largest buyer was Geode Capital Management, adding an estimated $21.9K. The largest seller was Goldman Sachs, exiting entirely with an estimated $18.8K sold.

  • 41 institutional investors held VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) as of Q2 2024, up from 36 in Q1 2024.
  • Funds reported $1.79M of VBI Vaccines, Inc. New Common Stock (Canada) stock for Q2 2024, up 11% quarter-over-quarter.
  • 8 funds opened new VBI Vaccines, Inc. New Common Stock (Canada) positions in Q2 2024 and 3 closed out, a net change of +5 holders.
  • The largest VBI Vaccines, Inc. New Common Stock (Canada) buyer in Q2 2024 was Geode Capital Management, an estimated $21.9K added.
  • The largest VBI Vaccines, Inc. New Common Stock (Canada) seller in Q2 2024 was Goldman Sachs, an estimated $18.8K sold.

Based on aggregated 13F filings for Q2 2024.